96891 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa Plasmodium
Malaria pre-erythrocytic antigens as a fusion polypeptide and their use in the elicitation of a protective immune response in a host
#2AUTOMATED HEART VALVE MANUFACTURING
#3IMMUNOGENICITY OF PLASMODIUM VIVAX CIRCUMSPOROZOITE PROTEIN NANOPARTICLE VACCINES
#4PFCSP-BASED IMMUNOGENS AND RELATED COMPOSITION AND METHODS
#5MALARIA VACCINE
#6AUTOMATED HEART VALVE MANUFACTURING
#7NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
#8SAPONIN-BASED ADJUVANTS AND VACCINES
#9A CONJUGATE FOR USE IN LOCALISING A MOLECULE TO THE VASCULAR ENDOTHELIUM
#10COMPOSITIONS FOR AND METHODS OF TREATING AND/OR PREVENTING MALARIA
#11METHOD OF TREATMENT OF MALARIA BY TARGETTING OPEN READING FRAMES
#12Automated heart valve manufacturing
#13SYNTHETIC PLASMODIUM ANTIGENS, COMPOSITIONS, AND USES THEREOF
#14NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF
#15COMPOSITIONS AND METHODS FOR TARGETING PLASMODIUM MALE GAMETE PROTEIN TO BLOCK MALARIA PARASITE TRANSMISSION
#16IMMUNOGENIC PEPTIDES, COMPOSITIONS, AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF MALARIA
#17Vaccine for falciparum malaria
#18MATERIALS AND METHODS FOR MAKING SEXUAL STAGE PLASMODIUM PARASITES
#19Automated heart valve manufacturing
#20PLASMODIUM VIVAX MALE GAMETE FUSION PROTEIN PVHAP2 AND THE PUTATIVE PROLIFERATING-CELL NUCLEOLAR ANTIGEN P120 AS RELAPSE BIOMARKERS
#21Compositions and methods of enhancing immune responses to or limiting infection
#22Automated heart valve manufacturing devices and methods
#23Multivalent malaria transmission-blocking vaccines
#24Doubly attenuated late liver stage malaria parasites and related compositions and methods
#25VIRAL-VECTORED VACCINE FOR MALARIA
#26Malaria transmission blocking vaccine
#27Vaccine for falciparum malaria
#28MALARIA VACCINE AND METHODS FOR PRODUCING SAME
#29Targeted vaccination in the liver
#30Malaria pre-erythrocytic antigens as a fusion polypeptide and their use in the elicitation of a protective immune response in a host
#31ANTIMALARIAL DRUG, MALARIA TREATMENT METHOD, SCREENING METHOD FOR CANDIDATE SUBSTANCE FOR MALARIA TREATMENT, MALARIA SEVERITY MARKER, METHOD FOR TESTING RISK OF SEVERE MALARIA, AND TEST REAGENT
#32Attenuation system and use thereof
#33Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
#34USES OF PARASITE MACROPHAGE MIGRATION INHIBITORY FACTORS
#35Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
#36MALARIA VACCINE
#37Nanoparticle platform for antibody and vaccine delivery
#38Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
#39IMMUNOGENS OBTAINED FROM PLASMODIUM YOELII USING QUANTITATIVE SEQUENCELINKAGE GROUP SELECTION METHOD
#40Malaria vaccine and methods for producing same
#41Vaccine for falciparum malaria
#42Doubly attenuated late liver stage malaria parasites and related compositions and methods
#43THERMOSTABLE VARIANTS OF P. FALCIPARUM PFRH5 WHICH CAN BE PRODUCED IN BACTERIAL CELLS
#44MALARIA VACCINE
#45Malaria vaccine
#46Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections
#47ARTIFICIAL FORISOME BODIES WITH SEO-F FUSION PROTEINS, PLANT OR YEAST CELLS WITH VECTORS FOR ENCODING THESE PROTEINS AND VECTORS FOR ENCODING SEO-F FUSION PROTEINS
#48Compositions and methods of enhancing immune responses to or limiting infection
#49COMPOSITIONS COMPRISING CelTOS IMMUNOGENS AND ANTIBODIES AND METHOD OF USE THEREOF
#50Compositions and methods for detection of malaria biomarkers
#51IDENTIFICATION AND PRODUCTION OF HIGH AFFINITY IGM ANTIBODIES AND DERIVATIVES THEREOF
#52Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
#53ANTI-PLACENTA-CHONDROITIN-SULFATE CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF
#54Peptides having tetrahedral mimicking groups as inhibitors of rhomboid proteases
#55Adenovirus based malaria vaccine encoding and displaying a malaria antigen
#56Anti-malarial antibodies that bind circumsporozoite protein
#57Vaccines with interleukin-33 as an adjuvant
#58Production of in vivo N-deglycosylated recombinant proteins by co-expression with endo H
#59IMMUNOASSEMBLIN (IA) PROTEIN COMPLEXES
#60IMMUNOTHERAPEUTIC TARGETING OF PLACENTAL-LIKE CHONDROITIN SULFATE USING CHIMERIC ANTIGEN RECEPTORS (CARS) AND IMMUNOTHERAPEUTIC TARGETING OF CANCER USING CARS WITH SPLIT-PROTEIN BINDING SYSTEMS
#61Compositions and methods of enhancing immune responses to or limiting infection
#62VAR2CSA-drug conjugates
#63Messenger UNA molecules and uses thereof
#64COMPOSITION AND USES THEREOF
#65Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
#66Mosquito saliva protein malaria vaccine
#67Vaccine for falciparum malaria
#68Artificial antigen produced using partial sequence of enolase protein originated from plasmodium falciparum, and method for producing same
#69Vaccine for malaria
#70Three-component-multistage malaria vaccine
#71Treatment and prevention of malaria
#72Mucin-associated surface protein as a vaccine against chagas disease
#73Multi-component-multistage malaria vaccines
#74Uses of parasite macrophage migration inhibitory factors
#75Targeting of chondroitin sulfate glycans
#76Plasmodium falciparum antigens
#77Composition comprising branched multipeptide vaccine and vaccine comprising the same
#78Targeting of chondroitin sulfate glycans
#79Methods and compositions for expressing functional class XIV myosin
#80MOLECULAR ADJUVANT
#81AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
#82Subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides
#83MALARIA VACCINATION
#84Vaccines with interleukin-33 as an adjuvant
#85Influenza nucleoprotein vaccines
#86Inducing Cellular Immune Responses to Plasmodium Falciparum Using Peptide and Nucleic Acid Compositions
#87Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
#88Vaccine comprising AMA1 and RON2
#89Composition and uses thereof
#90MESSENGER UNA MOLECULES AND USES THEREOF
#91Treatment and prevention of malaria
#92Vaccines against apicomplexan pathogens
#93Plasmodium falciparum antigens
#94Process for purifying recombinant circumsporozoite protein
#95Soluble recombinant plasmodium falciparum circumsporozoite protein, use in vaccines, methods of making and uses thereof
#96Recombinantly expressed plasmodium CelTOS antigen and methods of use thereof
#97Assay for inhibitors of equilibrative or concentrative nucleoside transporters
#98Compositions and methods of enhancing immune responses to or limiting infection
#99Lentiviral vector based immunological compounds against malaria
#100Adenovirus vectors
#101sporozoite and liver stage antigens
#102Artificial forisome body with SEO-F fusion proteins, plant or yeast cells comprising vectors which code for these proteins, as well as vectors which code for SEO-F fusion proteins
#103USE OF P47 FROM PLASMODIUM FALCIPARUM (PFS47) OR PLASMODIUM VIVAX (PVS47) AS A VACCINE OR DRUG SCREENING TARGETS FOR THE INHIBITION OF HUMAN MALARIA TRANSMISSION
#104NOVEL MALARIA TRANSMISSION-BLOCKING VACCINES
#105Conformation-stabilized TRAP antigens
#106Recombinant polypeptide construct comprising circumsporozoite protein HLA class I restricted T-cell epitopes
#107Influenza nucleoprotein vaccines
#108Lyme disease vaccine, genetic construct, recombinant protein, method for designing genetic construct, method for producing vaccine, method for producing recombinant proteins, use of recombinant proteins in the production of lyme disease vaccine
#109Mucin-associated surface protein as vaccine against Chagas disease
#110antigens
#111CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES
#112Malaria vaccine
#113Targeting of chondroitin sulfate glycans
#114Immunotherapy targeting intracellular pathogens
#115Malaria vaccine
#116Vaccine for malaria
#117Expression vectors for cell-surface expression of polypeptides comprising a transmembrane domain of glycophorin A
#118Algal produced malarial transmission blocking vaccines
#119In vivo de-glycosylation of recombinant proteins by co-expression with PNGase F
#120Blood stage malaria vaccine
#121Production of a cysteine rich protein
#122Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
#123Process for purifying recombinant circumsporozoite protein
#124Treatment and prevention of malaria
#125Consensus antigen constructs and vaccines made therefrom, and methods of using the same to treat malaria
#126Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression
#127Treatment and prevention of malaria
#128PLANT-DERIVED CHOLERA AND MALARIA VACCINE
#129Conjugates of surface proteins as malaria vaccines
#130Vaccines against pregnancy-associated malaria
#131RECOMBINANT PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEINS 4 AND 5 AND THEIR USE
#132Synthetic antigen based on the ligand domain of the duffy binding protein
#133Exosomes derived from reticulocytes infected with sp., method for obtaining them and uses thereof
#134Vaccine for Modulating Between T1 and T2 Immune Responses
#135Vaccine for modulating between T1 and T2 immune responses
#136STABLE IMMUNOGENIC PROTEIN HAVING MULTIPLE CYSTEINES MOLECULES PROCESS THEREFOR AND COMPOSITION THEREOF
#137Plasmodium falciparum antigens
#138Recombinantly expressed CelTOS antigen and methods of use thereof
#139ENHANCED MALARIA MSP-1 SUBUNIT VACCINE
#140VIRUS LIKE PARTICLES COMPRISING TARGET PROTEINS FUSED TO PLANT VIRAL COAT PROTEINS
#141Sub-region of a plasmodium protein with improved vaccine potential, and medical uses thereof
#142Recombinant merozoite surface proteins 4 and 5 and their use
#143Production of recombinant proteins in ciliates and uses thereof
#144Methods of administering PIF agonist peptides and uses thereof
#145Recombinant viral-based malaria vaccines
#146Compositions and Methods for Modulating a Cytotoxic T Lymphocyte Immune Response
#147Malaria vaccine
#148POLYPEPTIDE CARRIER PROTEIN
#149Adenovirus vectors
#150PLASMODIUM FALCIPARUM ANTIGENS AND METHODS OF USE
#151IMMUNOTHERAPY TARGETING INTRACELLULAR PATHOGENS
#152Plasmodium Vaccines, Antigens, Compositions and Methods
#153Nucleotide and amino acid sequences encoding an exported protein 1 derived from and uses thereof
#154Methods and compositions for treating and preventing malaria using an invasion ligand directed to a protease-resistant receptor
#155MALARIA VACCINE BASED ON FRAGMENTS AND COMBINATION OF FRAGMENTS OF THE CS PROTEIN OF PLASMODIUM VIVAX
#156MSP-1 PROTEIN PREPARATIONS FROM PLASMODIUM
#157Chimeric MSP-based malaria vaccine
#158MSP2 ANTIGENIC PEPTIDES AND THEIR USE
#159VACCINE AND IMMUNIZATION METHOD USING PLASMODIUM ANTIGEN 2
#160Malaria vaccine compositions and constituents which elicit cell mediated immunity
#161Methods of screening for compounds that inhibit the biosynthesis of GPI in malaria parasites
#162GENE SITE SATURATION MUTAGENESIS
#163METHODS AND REAGENTS FOR VACCINATION WHICH GENERATE A CD8 T CELL IMMUNE RESPONSE
#164Recombinant viral-based malaria vaccines
#165Plasmodium falciparum sporozoite and liver stage antigens
#166Methods for detecting virulent , for evaluating virulence, and for screening new drugs employing the 3′ UTR of SUB2 and the SUB2 serine protease
#167MALARIA VACCINE
#168COMPOSITIONS OF TOLL-LIKE RECEPTOR AGONISTS AND MALARIA ANTIGENS AND METHODS OF USE
#169Plasmodium falciparum antigens and their vaccine and diagnostic applications
#170Recombinant malaria vaccine
#171Binding domain of reticulocyte binding proteins
#172RECOMBINANT PROTEIN CONTAINING A C-TERMINAL FRAGMENT OF PLASMODIUM MSP-1
#173IDENTIFICATION OF A CONSERVED REGION OF PLASMODIUM FALCIPARUM MSP3 TARGETED BY BIOLOGICALLY ACTIVE ANTIBODIES
#174Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#175ADENOVIRAL VECTOR-BASED MALARIA VACCINES
#176System and method for identifying complex patterns of amino acids
#177Vaccines for malaria
#178Plant-Derived Cholera and Malaria Vaccine
#179CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
#180Purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from carrying a Glycosyl-phosphatidyl-inositol group (GPI)
#181Polynucleotides and polypeptides involved in gestational malaria, and biological applications
#182Nucleotide and amino acid sequences encoding an exported protein 1 derived from and uses thereof
#183REPLIKINS AND METHODS OF IDENTIFYING REPLIKIN-CONTAINING SEQUENCES
#184REPLIKIN PEPTIDES AND ANTIBODIES THEREFOR
#185PLASMODIUM AXENIC LIVER STAGES AS A NONINFECTIOUS WHOLE ORGANISM MALARIA VACCINE
#186ANTI-MALARIA VACCINE COMPOSITIONS AND USES THEREOF
#187Conjugates of surface proteins as malaria vaccines
#188LSA-5 liver stage and blood stage antigen of , immunogenic composition comprising said antigen, and vaccines against malaria
#189Malaria vaccines
#190Recombinant viral-based malaria vaccines
#191Protein composition for inducing an immune response in a vertebrate comprising a plurality of protein variants covering the heterogeneity of a single antigen, AMA1
#192liver stage antigens
#193Vaccines for malaria
#194PLASMODIUM FALCIPARUM ANTIGENS INDUCING PROTECTIVE ANTIBODIES
#195Methods and reagents for vaccination which generate a CD8 T cell immune response
#196VACCINE AGAINST MALARIA, BASED ON THE 200L SUBUNITI OF PLASMODIUM VIVAX MSP1 PROTEIN
#197Recombinant merozoite surface proteins 4 and 5 and their use
#198Vaccines for malaria
#199NOVEL METHOD AND COMPOSITIONS
#200Split-core-particles for the presentation of foreign molecules, especially for vaccine applications, and method for their production
#201Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
#202Recombinant merozoite protein-1vaccine
#203Antigenic polypeptide SE36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen
#204Methods and reagents for vaccination which generate a CD8 T cell immune response
#205COMPOUNDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF MALARIA
#206REPLIKIN PEPTIDES IN RAPID REPLICATION OF GLIOMA CELLS AND IN INFLUENZA EPIDEMICS
#207and genes and uses thereof
#208Polypeptide carrier protein
#209and genes and uses thereof
#210Identification of a conserved region of MSP3 targeted by biologically active antibodies
#211Methods and compositions for treating and preventing malaria (2)
#212Malaria Vaccines
#213Methods and reagents for vaccination which generate A CD8 T cell immune response
#214Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#215Adenoviral vector-based malaria vaccines
#216REPLIKIN PEPTIDES AND ANTIBODIES THEREFORE
#217Gene site saturation mutagenesis
#218Chondroitin Sulphate a Binding Domains
#219Antigenic polypeptide SE36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen
#220Chimeric MSP-based malaria vaccine
#221PIF peptides biologic activities, site of action, and the antibody to detect PIF
#222Antigenic peptides and their use
#223Plasmodium liver stage antigens
#224Anti-malaria vaccine
#225Recombinant merozoite surface proteins 4 and 5 and their use
#226Replikins and methods of identifying replikin-containing sequences
#227VACCINES FOR BLOCKING TRANSMISSION OF PLASMODIUM VIVAX
#228Method and compositions for prevention and treatment of malaria infections
#229Mycobacteria expressing HIV-1 and malaria antigens
#230ADENOVIRAL VECTOR-BASED MALARIA VACCINES
#231Recombinant viral-based malaria vaccines
#232DNA sequences encoding peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes
#233Malaria MSP-1 C-terminal enhanced subunit vaccine
#234Malaria vaccines
#235IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF
#236Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
#237Recombinant merozoite protein-1vaccine
#238Unique DNA and polypeptide sequences based on the circumsporozoite protein of
#239Profilin and related immunomodulatory ligands
#240Method of producing partial peptide of enolase protein from
#241Novel therapeutic target for protozoal diseases
#242Plasmodium vivax blood stage antigens, PVESP-1, antibodies and diagnostic assays
#243MSP-3-like family of genes
#244Recombinant viral-based malaria vaccines
#245Therapeutic target for protozoal diseases
#246Recombinant viral-based malaria vaccines
#247Glycine-rich proteins, their coding genes and applications
#248Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#249Crystal structure of erythrocyte binding domain of EBA-175
#250Malaria vaccines
#251Recombinant protein containing a C-terminal fragment of Plasmodium MSP-1
#252Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
#253Stabilized immunogenic HBc chimer particles
#254Methods for detecting virulent , for evaluating virulence, and for screening new drugs employing the 3′UTR of SUB2 and the SUB2 serine protease
#255Antigenic polypeptide SE36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen
#256Polyepitope carrier protein
#257GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
#258Plasmodium falciparum AMA-1 protein and uses thereof
#259Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes, antibodies which bind to the proteins, and methods for detecting infection, stage of infection and vaccines for protecting against infection
#260Method of screening
#261Process for producing antigenic substance
#262antigens inducing protective antibodies
#263Methods for vaccinating against malaria
#264Peptide sequences specific for the hepatic stages of bearing epitopes capable of stimulating the T lymphocytes
#265Methods of screening for compounds that inhibit the biosynthesis of GPI in malaria parasites
#266antigens and methods of use
#267Anti-plasmodium compositions and methods of use
#268Antigenic peptides
#269Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
#270Expression, purification and uses of a liver stage antigen 1 polypeptide
#271Identification of a conserved region of MSP3 targeted by biologically active antibodies
#272System and method for identifying complex patterns of amino acids
#273Malaria vaccine
#274Recombinant protein containing a C-terminal fragment of MSP-1
#275Malarial pre-erythrocytic stage polypeptide molecules
#276antigens inducing protective antibodies
#277Recombinant viral-based malaria vaccines
#278Vaccine based on a cellular penetration factor from an apicomplexan parasite
#279Universal T-cell epitopes for anti-malarial vaccines
#280Compositions and methods for modulating a cytotoxic T lymphocyte immune response
#281Plasmodium falciparum erythrocyte binding protein baebl for use as a vaccine
#282Merozoite surface protein 1 lacking glycosylation sites
#283Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
#284Malaria immunogen and vaccine
#285Antibodies which bind to proteins involved in cytoadhesion of plasmodlum falciparum ring-stage-infected erythrocytes
#286Production of lysosomal enzymes in plants by transient expression
#287AntiI-protozoal vaccine
#288GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
#289Saturation mutagenesis in directed evolution
#290Recombinant process for preparing a complete malaria antigen gp190/MSP1
#291Baculovirus produced vaccine
#292Phosphorous organic compounds and their use
#293antigens and their vaccine and diagnostic applications
#294Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
#295Proteins involved in cytoadhesion of plasmodlum falciparum ring-stage-infected erythrocytes, antibodies which bind to the proteins, and methods for detecting infection, stage of infection and vaccines for protecting against infection
#296polypeptides and methods of using same
#297Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines
#298Synthetic plasmodium antigens, compositions, and uses thereof
#299TAA/CD4OL composition/vaccine for malaria
#300Synthetic antigen based on the ligand domain of the plasmodium vivax duffy binding protein